Last updated on RxList: 9/28/2020
Qoliana Side Effects Center

What Is Qoliana?

Qoliana (brimonidine tartrate ophthalmic solution) is a selective alpha-2-adrenergic agonist used for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Qoliana is available in generic form.

Common side effects of Qoliana include:

  • eye redness,
  • inflammation,
  • itching, and
  • tearing

Other side effects of Qoliana include burning sensation, high blood pressure (hypertension), allergic reaction in the eyes, dry mouth, and visual disturbances.

The recommended dose is one drop of Qoliana, 0.15% in the affected eye(s) three-times daily, approximately 8 hours apart. Qoliana may interact with beta-blockers (ophthalmic and systemic), anti-hypertensives, cardiac glycosides, CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics), tricyclic antidepressants, and monoamine oxidase (MAO) inhibitors. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Qoliana. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Our Qoliana (brimonidine tartrate ophthalmic solution) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Pink Eye (Conjunctivitis) Symptoms, Causes, Treatments See Slideshow
Qoliana Professional Information


Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions occurring in approximately 10-20% of the subjects included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritis.

Adverse reactions occurring in approximately 5-9% of the subjects included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.

Reactions occurring in approximately 1-4% of subjects included: allergic reaction, arthralgia, arthritis, asthenia, blepharitis, blepharoconjunctivitis, blurred vision, bronchitis, cataract, chest pain, conjunctival edema, conjunctival hemorrhage, conjunctivitis, cough, dizziness, diabetes mellitus, dyspepsia, dyspnea, epiphora, eye discharge, eye dryness, eye irritation, eye pain, eyelid edema, eyelid erythema, fatigue, flu syndrome, follicular conjunctivitis, foreign body sensation, gastrointestinal disorder, headache, hypercholesterolemia, hypotension, infection, insomnia, joint disorder, keratitis, lid disorder, osteoporosis, pharyngitis, photophobia, rash, rhinitis, sinus infection, sinusitis, somnolence, stinging, superficial punctate keratopathy, tearing, visual field defect, vitreous detachment, vitreous disorder, vitreous floaters, and worsened visual acuity.

The following reactions were reported in less than 1% of subjects: corneal erosion, nasal dryness, and taste perversion.

Postmarketing Experience

The following adverse reactions have been identified during post-marketing use of brimonidine tartrate ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to brimonidine tartrate ophthalmic solutions, or a combination of these factors, include: bradycardia, iritis, miosis, skin reactions (including, eyelid pruritis, and vasodilation), and tachycardia. Apnea, bradycardia, hypotension, hypothermia, hypotonia, and somnolence have been reported in infants receiving brimonidine tartrate ophthalmic solutions.

Read the entire FDA prescribing information for Qoliana (Brimonidine Tartrate Ophthalmic Solution)


What causes dry eyes? See Answer

© Qoliana Patient Information is supplied by Cerner Multum, Inc. and Qoliana Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors